Gilead Sciences to acquire Ouro Medicines, expanding autoimmune therapy portfolio [Yahoo! Finance]
Gilead Sciences, Inc. (GILD)
Last gilead sciences, inc. earnings: 4/30 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investors.gilead.com
Company Research
Source: Yahoo! Finance
Gilead Sciences Inc (NASDAQ:GILD, XETRA:GIS) announced it has entered into a definitive agreement to acquire Ouro Medicines, a privately held biotech company developing T cell engager therapies for autoimmune diseases. The acquisition adds OM336 (gamgertamig), a clinical-stage BCMAxCD3 bispecific T cell engager, to Gilead's inflammation portfolio. The therapy is designed to provide rapid and deep B cell depletion following a limited subcutaneous treatment course. In Phase 1/2 clinical studies, OM336 has shown efficacy and a differentiated safety profile after a single treatment cycle in severe antibody-mediated conditions, including autoimmune hemolytic anemia (AIHA) and immune thrombocytopenia (ITP). The US Food and Drug Administration has granted OM336 both Fast Track and Orphan Drug Designation for these indications. Registrational studies are expected to begin in 2027. “BCMA is a validated target with emerging data demonstrating potentially transformative outcomes in auto
Show less
Read more
Impact Snapshot
Event Time:
GILD
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
GILD alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
GILD alerts
High impacting Gilead Sciences, Inc. news events
Weekly update
A roundup of the hottest topics
GILD
News
- Gilead Sciences: Caution After A Re-Rating Amidst New Concentration Risks [Seeking Alpha]Seeking Alpha
- Is Gilead (GILD) a Buy as Wall Street Analysts Look Optimistic? [Yahoo! Finance]Yahoo! Finance
- Gilead: Why The 'Immune System Company' Pivot Is No Longer A Bargain (Downgrade) [Seeking Alpha]Seeking Alpha
- Gilead to Acquire Ouro Medicines in $2.18B Deal, Expand Inflammation Pipeline [Yahoo! Finance]Yahoo! Finance
- Gilead Strengthens Inflammation Portfolio With Ouro Medicines Deal [Yahoo! Finance]Yahoo! Finance
GILD
Earnings
- 2/10/26 - Beat
GILD
Sec Filings
- 3/27/26 - Form 144
- 3/26/26 - Form SCHEDULE
- 3/20/26 - Form ARS
- GILD's page on the SEC website